Teicoplanin sodium structure
|
Common Name | Teicoplanin sodium | ||
---|---|---|---|---|
CAS Number | 184539-13-7 | Molecular Weight | 1564.3-1907.7 | |
Density | N/A | Boiling Point | N/A | |
Molecular Formula | N/A | Melting Point | N/A | |
MSDS | N/A | Flash Point | N/A |
Use of Teicoplanin sodiumTeicoplanin sodium (Antibiotic MDL-507 sodium) is a potent lipoglycopeptide antibiotic. Teicoplanin sodium shows antiviral activity for HIV-1, SARS-CoV1 and SARS-CoV2. Teicoplanin sodium shows anti-MRSA activity[1][2]. |
Name | Teicoplanin sodium |
---|
Description | Teicoplanin sodium (Antibiotic MDL-507 sodium) is a potent lipoglycopeptide antibiotic. Teicoplanin sodium shows antiviral activity for HIV-1, SARS-CoV1 and SARS-CoV2. Teicoplanin sodium shows anti-MRSA activity[1][2]. |
---|---|
Related Catalog | |
Target |
MRSA[2] |
In Vitro | Teicoplanin sodium 显示出抗病毒活性,对 HEK293T 细胞中的 HIV-luc/SARS-CoV-S 病毒、A549 细胞中的 2019-nCoV-Spike-病毒和Vero E6 细胞中的 SARS-CoV-2 病毒的 IC50 值分别为 0.39、1.66、15.7 µM[1]。 Teicoplanin sodium 可抑制人 CEM 细胞培养物中的 HIV-1 病毒,EC50 值为 17 µM[1]。 其机制是通过 Teicoplanin sodium 亲脂部分与酶的相互作用抑制抑制组织蛋白酶 L 活性并阻止 SARS-CoV 从晚期内体释放[1]。 Teicoplanin sodium 表现出抗 MRSA 活性,对 MRSA ATCC 43300 的 MIC 值为 0.5 mg/L[2]。 |
In Vivo | Teicoplanin sodium (10, 30 mg/kg; i.v.) 在小鼠 MRSA 大腿感染模型中表现出剂量依赖性的总细菌密度下降[2]。 Animal Model: 20-30 g, Male CD1 mice (2 * 106 cfu/mL MRSA (43 300) 50 µL; murine thigh infection model)[2] Dosage: 10, 30 mg/kg Administration: I.v.; once every 12 h Result: Showed a dose-dependent decline in the total bacterial density with the total bactericidal effect was achieved with dosages of ≥10 mg/kg/day and suppression of resistance with dosages ≥30 mg/kg/day. |
References |
Molecular Weight | 1564.3-1907.7 |
---|